Our objective was to assess the economic impact of a new cytokine therapy that was being compared to standard therapy as supportive care in patients receiving autologous bone marrow transplantation for treatment of lymphoma. We performed an economic study accompanying a multicenter, randomized, controlled clinical trial in academic medical centers. One hundred and fifteen patients consented to participate in a parallel economic study of a randomized controlled trial of sequential IL-3 followed by GM-CSF vs GM-CSF alone after autologous bone marrow transplantation. We measured costs and quality-adjusted survival over a 13-month follow-up period. For the 13-month study period, the total cost estimates were $79 892 (95% CI $69 343 to $90 544) for patients receiving GM-CSF alone and $89 651 (95% CI $79 769 to $102 114) for patients receiving IL-3/GM-CSF. The difference was not statistically significant. During the 13-month study period, the total number of quality-adjusted life-months in the GM-CSF arm was 6.67 (95% CI 5.75 to 7.56) months, while the total number of quality-adjusted life-months in the IL-3 arm was 6.26 (95% CI 5.34 to 7.15) months. The difference in quality-adjusted life-months between the two treatment arms was not statistically significant. We conclude that economic analysis of a phase III clinical trial of IL-3/GM-CSF compared with GM-CSF alone showed no significant effect of IL-3 on the costs of care for patients undergoing bone marrow transplantation for a period of up to 13 months after the procedure. This study demonstrates the feasibility of prospective economic evaluation within phase III trials of new cancer therapies. Data from this type of economic protocol could be used to help physicians, patients and managed care organizations understand the effect of new treatments from both a clinical and an economic perspective.
Investigators have recently developed novel clinical therapies to improve supportive care for patients undergoing autologous bone marrow transplantation (ABMT). More specifically, they have proposed therapies to help prevent the severe granulocytopenia and thrombocytopenia that previously persisted for 3 to 4 weeks after bone marrow infusion.
1 Both G-CSF and GM-CSF have been shown to decrease the time until neutrophil engraftment for patients undergoing ABMT. However, despite a reduction in time to neutrophil engraftment, prolonged periods of clinically significant thrombocytopenia are still experienced by patients undergoing ABMT. For this reason, interleukin-3 (IL-3) was proposed as additional supportive therapy for patients undergoing ABMT to stimulate early platelet recovery. 2 The growth factor IL-3 regulates the proliferation and differentiation of hematopoietic and lymphoid cells and stimulates the growth of early progenitors of several lineages in vitro. 3, 4 We report the results of a prospective study designed to assess the economic effect of IL-3 cytokine therapy on a population of patients undergoing ABMT. Prospective economic assessment of new cancer treatments during the clinical development process is a relatively recent development. [5] [6] [7] [8] [9] [10] This assessment measures the costs of treatment for patients, compares these costs to the clinical benefits received by patients, 5 and offers the potential for improved decision making regarding adoption of new medical technologies in an increasingly constrained health care system.
Economic assessment is not a simple calculation of the resources used by patients in a trial. For example, in this study, we defined the appropriate time horizon for the economic evaluation. Because transplant patients may continue to require sustained levels of resource use after their initial procedure, this study followed patients for a period of up to 13 months after their transplant hospitalization. Furthermore, because transplant services are offered at specialized centers while post-transplant care is often provided by community oncologists, we developed a specific program for follow-up of study patients throughout the study period. We also assessed the effect of treatment on patients by measuring their quality of life on a quarterly basis. Finally, we present an analysis that addresses specific statistical issues related to the evaluation of economic data collected within clinical trials.
Patients and methods

Clinical trial
The clinical study was a randomized, double-blind, placebo-controlled trial of supportive care after ABMT for patients with Hodgkin's or non-Hodgkin's lymphoma. The study compared two treatment regimens: 21 days of GM-CSF beginning on the day of marrow infusion compared with 10 days of IL-3 followed by 11 days of GM-CSF with IL-3 beginning on the day of marrow infusion. The primary endpoint for the clinical trial was a 42-day assessment, with a safety assessment continuing for 12 months. The trial enrolled 206 patients in 16 centers from June 1993 to March 1995.
Clinical protocol:
The primary endpoints of the clinical study included time to platelet recovery to a count of 20 000 cells/l and time to neutrophil recovery to a cell count of 500 cells/l. Secondary endpoints included the number of platelet transfusions, time to transfusion independence, and other engraftment parameters, including platelet counts of 50 000 cells/l, ANC Ͼ 100 cells/l, and ANC Ͼ 1000 cells/l, as well as time to meeting hospital discharge criteria.
Clinical results: Preliminary clinical results are available at this time. Of the 206 patients, 104 were randomized to IL-3 followed by GM-CSF, and 102 patients were randomized to GM-CSF alone. The median number of days for platelet recovery to reach Ͼ20 000/l was 25 days (range, 4-42) in the IL-3/GM-CSF arm and 22 days (range, 4-42) in the GM-CSF arm (P = 0.29); for neutrophil recovery to ANC Ͼ 500/l, 17 days (range, in the IL-3/GM-CSF arm and 16 days (range, 4-46) in the GM-CSF arm (P = 0.13). These preliminary results indicate that there is no difference in hematopoietic recovery between the sequential administration of IL-3/GM-CSF following ABMT compared to the use of GM-CSF alone. 11 
Parallel economic protocol
Of the 206 patients enrolled in the clinical arm of this study, 115 were successfully enrolled in the parallel economic study. The parallel economic protocol included rolling admission to the study, with a fixed stopping date 6 months after the last patient was enrolled in the clinical protocol. Thus, the minimum protocol-defined follow-up of patients was 6 months, and the maximum follow-up was 13 months. Reasons for nonparticipation of clinical trial patients included enrollment in the clinical trial before institutional review board approval of the parallel economic protocol (45 patients), nonparticipation of the clinical site (16 patients) and patient refusal (30 patients).
Data collection: Economic evaluation included assessment of patients' initial hospital length of stay and post-discharge resource consumption (see Figure 1) . Monthly patient telephone interviews were conducted to assess the use of a selected set of resource categories, including rehospitalization, chemotherapy, radiation therapy, transfusion, out- patient procedures and professional services. Data collection also included assessment of patients' health-related quality of life as measured by the EuroQol EQ-5D instrument (hereafter referred to as EuroQol) at baseline, 3 months, 6 months, 9 months and 1 year. 21 Patients who consented to participate in the economic protocol were contacted by telephone at the time of discharge from the hospitalization for ABMT to arrange monthly follow-up telephone calls. During each of these monthly follow-up calls, patients were asked whether they received any of the specific study resource items over the previous month and, if so, to quantify them. Hospital bills were obtained from the study hospitals for the hospitalizations for ABMT. If a patient was rehospitalized after the initial hospitalization for ABMT, the name of the hospital was obtained so that bills could be collected.
Cost estimates
Cost estimates were made for each of the specific resource categories assessed in this study. All costs are reported in 1995 dollars.
ABMT hospitalization
Hospital charges for hospitalizations for ABMT after randomization were derived from hospital bills. These bills report the resources utilized by patients during the hospitalization but do not include physician services. Hospital bills contain information on charges for specific clinical services. Charges are relatively unique to the United States health care system in that they represent the 'list' price for services, which usually is greater than the costs of actually providing the services. We converted these charges into costs to better assess the actual utilization of resources by study patients. Costs are more representative of economic data available outside the United States. Hospitalization costs were computed using Medicare hospital-wide cost-tocharge ratios that were obtained from the Medicare cost report data set. 12 In cases for which complete hospital bills were not available (five of 115 patients), hospital cost data were imputed using ordinary least-squares regression. Explanatory variables were derived from the clinical case report form and included baseline patient characteristics and clinical parameters.
Where available, we collected physician billing records for the hospitalization for ABMT either from the faculty practice plan when a hospital had a central physician billing office or from up to five individual clinical departments (medicine, surgery, pathology, oncology and radiology). Data were collected as Current Procedural Terminology (CPT) codes for each visit 13 and were assigned costs using the 1995 Medicare fee schedule. 12 Medicare reimburses physician services based on an evaluation of physician effort required to perform the service. These workload assessments are based on the resource-based relative value scale (RBRVS) 14 and are predictive of physician costs outside the United States. 15 Services are identified using CPT codes, which were developed for physician services in the United States. These codes are more specific than procedural classifications using the International Classification of Diseases. 16 Because cytokine therapy was provided as part of the clinical protocol, costs for IL-3/GM-CSF were not included in this analysis. However, the projected costs of cytokine therapy would be equivalent for the two study arms.
Post-discharge resource consumption
Six categories of post-discharge resource consumption were identified and followed in this study: rehospitalization, chemotherapy, radiation therapy, transfusions, outpatient surgeries and procedures, and provider visits.
Rehospitalization: Rehospitalization costs were computed from hospital bills (charges), again using hospital-wide cost-to-charge ratios. 17 When hospital billing data were not available (30 of 82 hospitalizations), a regression model was used to impute missing billing information by predicting costs per hospital day.
Chemotherapy: Chemotherapy costs were developed using standard doses and frequencies for each patient's selfreported chemotherapy regimen, including physician time for administration of intravenous medications.
Pharmaceutical drug costs were based on average wholesale prices, 18 while the cost of physician time was obtained from the Medicare fee schedule for chemotherapy administration. 12 Pharmaceutical prices may be higher in the United States than in other countries.
Radiation therapy: Radiation therapy costs were estimated based on initial cost for the first week of treatment, as well as subsequent costs. Again, costing estimates were based on standard regimens using the Medicare fee schedule.
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Transfusions: Six types of transfusions were collected in the study: packed red cells, white cells, platelet standard unit, platelet apheresed unit, fresh frozen plasma and whole blood. The costs of these services were based on proprietary cost data obtained from one university hospital.
Provider visits: Three types of provider visits were assessed in this study: physician, nurse and home health care. Costs of physician visits were computed by multiplying the length of visits (in hours and minutes) by the cost of doctor visits, again using the Medicare fee schedule for physician follow-up visits with CPT codes assigned for outpatient visits based on length of the visit. 12 Costs of nursing visits and the cost of home care were calculated by multiplying the duration of each visit by the hourly cost for registered nurses/nurse practitioners and home care services, respectively. Licensed practitioner and staff nurse costs were derived from the 1994 average annual salaries published by the American Association of Nurses. 19 Pervisit costs for home health care were obtained from statistics published by the National Association for Home Care. 20 Outpatient surgery and procedures: Each outpatient surgical and nonsurgical procedure was assigned a CPT code, with a cost assigned based on the Medicare fee schedule. 12 Missing outpatient data: When descriptive information on resource use was missing from any of the outpatient resource-use categories (for example, length of time with physician during a physician visit or a specific chemotherapy regimen), cost imputations were developed based on patient means when more than 1 month of data were available for that patient. Otherwise, the mean cost across all patients for that month was assigned to the patient with missing data.
Quality of life
Patient preferences for their health states were measured using the EuroQol thermometer, a visual analogue scale. 21 This instrument records patients' preferences for their health states on a zero-to-100 scale, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.
Missing data for the baseline EuroQol instrument were predicted using a robust estimation procedure with Huber correction for outliers. 22 Variables in this model included elapsed time since diagnosis, as well as other demographic and clinical characteristics. For missing follow-up EuroQol scores, the regression model included the baseline EuroQol score and a series of 0-1 categorical variables to represent time.
Analysis
In the economic assessment of this protocol, we developed four separate analyses. First, we assessed patient characteristics for participants and nonparticipants in the economic protocol. Second, we assessed the use of specific resources for patients in the two study arms. Third, we developed an analysis of the costs of care for patients in both arms of the study. Finally, we assessed the quality-of-life data reported for study patients. Had there been evidence of increased costs and improved outcome, we would also have compared the value for the cost of the intervention.
The analysis we used in assessing costs and quality of life was specifically designed to overcome problems of differential right-censoring of study data due to rolling study admission and, to a lesser extent, due to patient drop-out. As recently reported, 23 this method adjusts for differential right-censoring by reweighting the observed costs and quality-adjusted life-months (QALMs) of patients followed in the later study period and predicting the costs and QALMs of study participants as if they had all been available for the full 13 months of follow-up.
Patient characteristics: Univariate statistical tests were performed to determine whether there were significant differences in demographic and clinical characteristics measured at enrollment in the study between participants and nonparticipants in the economic protocol and to assess differences across the two treatment arms for participants in the economic protocol.
Because differences in two variables were statistically significant between participants and nonparticipants in the economic arm, univariate analyses were also conducted among participants and nonparticipants to detect treatment effects on length of stay during the hospitalization for ABMT and the number of cells reinfused (these two variables were collected as part of the clinical case report form and were available for all patients, including those who did not enroll in the economic study). Finally, to determine if there were trends in length of stay during the study period (eg longer lengths of stay for patients enrolled earlier in the study), a regression model was developed to assess length of stay for the hospitalization for ABMT based on date of patient enrollment in the clinical study.
Resource utilization: Resource utilization measures were compared for patients in the two treatment groups for the hospitalization for ABMT, rehospitalizations, and outpatient resource consumption. Comparisons of continuous variables were made using t-tests where appropriate.
Analysis of treatment costs:
The analysis of cost data consists of three stages. In the first, we estimate the probability of survival during each month of the trial using a survival analysis of study patients. Second, we predict the monthly costs among patients followed in the month (eg for the 12th month, we use data from patients randomized early enough in the trial to be observed at 1 year). Third, we took the sum of the products of monthly survival and monthly costs to represent the costs for each treatment group.
Survival analysis: Survival within the trial was estimated using a parametric failure time model assuming an underlying Weibull distribution. 24 The Weibull is a two-parameter model that allows the hazard to vary at a constant rate (unlike the single-parameter exponential distribution, which requires a constant hazard). The resulting parameters were used to predict the proportion of the population alive at monthly intervals during the trial.
Cost prediction: Monthly costs among survivors were assessed by computing the total of all inpatient and outpatient costs for patients for each of the 13 months in the study. Expected costs for the full study among randomized patients were calculated as the product of the monthly cost and the monthly probability of survival for patients in each study arm.
Confidence limits for cost estimates:
We used a nonparametric bootstrap procedure to construct 95% confidence intervals (CIs) around our cost projections and around the difference in cost between the treatment arms by sampling from the study patients with replacement. Differences in cost estimates were considered statistically significant if the 95% CI of the difference between the treatment arms excluded 0.
Analysis of quality-adjusted survival:
We calculated QALMs for the within-trial period for each study patient by assessing the area under their quality-adjusted survival curve. Because the EuroQol instrument was administered at randomization and every 3 months, we calculated QALMs by assessing the data on a quarterly basis. For each observation period, we calculated QALMs by multiplying the observed time period by the patient's average EuroQol score for that period among patients still available for follow-up. QALMs for each treatment group were estimated from patient data by calculating the product of the quarterly QALM and the probability of survival within the trial for patients in each study arm. This analysis adjusts for the differential right-censoring of quality-of-life data in a manner similar to that used for the analysis of the cost data.
Confidence limits for QALM estimates:
We also implemented a nonparametric bootstrap procedure to construct a 95% CI around our QALM projections and around the difference in QALM projections across treatment arms, as described above. We considered differences in the estimates of QALMs statistically significant if the 95% CI around the difference excluded 0.
Results
Patient characteristics
The baseline demographic and clinical characteristics for patients enrolled in the economic study were comparable and are presented in Table 1 . As shown, the only difference was a small but statistically significant difference in Karnofsky Performance Status between patients in the two arms of the study, with patients in the GM-CSF arm having a higher baseline performance score. There were no other a The mean baseline EuroQol score for both treatment groups is 75. This is somewhat larger than the mean baseline EuroQol score of IL-3 patients. This is due to a patient who gave his baseline health state a score of 5.
statistically significant differences between the treatment groups for any of the other baseline parameters.
We assessed the same variables for the 115 patients enrolled in the parallel economic protocol compared to the 91 patients not included in the economic study (not shown). The only variables that were significantly different between the two populations were the total length of stay during the hospitalization for ABMT and the number of cells reinfused during this hospitalization. The mean length of stay for the hospitalization for ABMT was 32.7 days for patients enrolled in the economic protocol, while the patients not included spent 37.0 days in the hospital (P = 0.01). Also, mean number of cells reinfused was 18.3 × 10 8 /kg body weight for patients in the economic arm, while the mean number of cells reinfused was 21.9 × 10 8 /kg body weight for patients not enrolled in the economic arm (P = 0.02). Among patients not enrolled in the economic study, there were no statistically significant differences in the number of cells reinfused or in the length of stay at the baseline hospitalization between the two treatment arms.
The regression predicting length of stay for the hospitalization for ABMT as a function of the date of randomization suggested that length of stay decreased during the entire study period (P = 0.017). This change may account for some of the difference in the baseline length of stay between patients in the economic protocol and patients not in the economic protocol since there was a delay in obtaining IRB approval for the economic protocol.
Resource utilization
ABMT hospitalization: Average length of stay for patients in the economic arm of the study is presented in Table 2 . There is no statistically significant difference across treatment groups (P = 0.4).
Rehospitalizations:
Patients in the GM-CSF treatment group had a total of 49 in-hospital stays while patients in the IL-3/GM-CSF arm had 33 such stays (see Table 2 ). However, the average length of stay for patients who were rehospitalized was shorter in the GM-CSF group (5.18 days) than in the IL-3/GM-CSF group (7.15 days) (P = 0.16). The total number of days in the hospital averaged 4.46 and 4.45 per patient for the two treatment arms, respectively (P = 0.913).
Outpatient resource consumption:
Patients in the GM-CSF arm averaged 1.37 outpatient visits per month compared to patients in the IL-3/GM-CSF arm, who averaged 1.63 outpatient visits per month. Overall, 33% of patients in the GM-CSF group and 38% of patients in the IL-3/GM-CSF group required radiation therapy or chemotherapy after discharge from their bone marrow transplant procedure. Also, 33% of patients required transfusions after discharge from the hospitalization for ABMT in the GM-CSF group, and 49% of patients required transfusion after discharge from the hospitalization for ABMT in the IL-3/GM-CSF group. Figures 2 and 3 illustrate the utilization of transfusion services and rehospitalization in the follow-up period for both study arms (including multiple events per patient).
Survival analysis
Results of the survival analysis indicated no difference in survival for patients across treatment arms. Patients in the GM-CSF arm had a predicted survival probability of 76% at 13 months compared to patients in the IL-3/GM-CSF, who had a predicted survival probability of 78%. Average follow-up time within the trial was 9.6 months in the GM-CSF arm and 9.1 months in the IL-3/GM-CSF arm. The P value for the difference in hospital stays is 0.913. c Among patients with rehospitalizations, the average hospital stay was 5.18 days and 7.15 days (P = 0.16), for GM-CSF and GM-CSF/IL-3, respectively. 
Cost estimates ABMT hospitalization costs:
The average cost in the GM-CSF arm was $69 002 for the hospitalization for ABMT, while the average cost in the IL-3/GM-CSF arm was $79 884. This difference was not statistically significant (P Ͼ 0.05).
Post-discharge resource utilization: For the 13-month study period, the difference in survival-weighted costs after discharge between the two treatment arms was not statistically significant (95% CI for the difference in post-discharge costs is Ϫ$8453-$6208, which includes 0). Postdischarge costs were $10 890 (95% CI $5979-$16 917) for patients in the GM-CSF arm and $9767 (95% CI $5650-$15 459) for patients in the IL-3/GM-CSF arm. In terms of outpatient resource utilization per patient month, patients receiving IL-3/GM-CSF generally had a higher cost per month for most categories of costs than did patients receiving GM-CSF alone: $33.04 vs $8.64 for chemotherapy, $34.18 vs $33.37 for radiation therapy, $55.21 vs $49.53 for transfusions, $52.92 vs $36.83 for professional services, and $15.99 vs $15.65 for outpatient surgeries and procedures. In contrast, patients who received GM-CSF/IL-3 incurred slightly lower rehospitalization costs than did patients receiving GM-CSF treatment alone, $814.58 vs $886.77.
Total costs: For the 13-month study period, the difference in total cost between treatment arms was not statistically significant (95% CI for the difference in total costs is Ϫ$4896-$26 698, which includes 0). The total cost estimates were $79 892 (95% CI $69 343-$90 544) for patients in the GM-CSF alone arm and $89 651 (95% CI $79 769-$102 114) for patients in the IL-3/GM-CSF arm. Cost data are presented in Table 3 .
Quality of life
Quality-adjusted survival results: During the 13-month study period, there was no statistically significant difference in QALMs between treatment arms (95% CI for the difference in QALMs is Ϫ1.68-0.89 which includes 0). The total QALMs in the GM-CSF arm were 6.67 months (95% CI 5.75-7.56 months), while the total QALMs in the IL-3/GM-CSF arm were 6.26 (95% CI 5.34-7.15 months) months.
Discussion
In an economic study that served as a parallel protocol to a phase III clinical trial, we found that the use of IL-3/GM-CSF had no effect on the costs of care for patients undergoing ABMT for treatment of Hodgkin's or non-Hodgkin's lymphoma compared with the use of GM-CSF alone.
In patients followed in our study, we found that the majority of resource use associated with ABMT patients occurred during the hospitalization for ABMT. Approximately 86% of the observed costs in GM-CSF patients and 89% of the observed costs in IL-3/GM-CSF patients were related to the transplant hospitalization. However, an important minority of patients required substantial additional resources over the year. Overall, 34% of patients were rehospitalized after the hospitalization for ABMT, and 39% required transfusions.
The magnitude of expenditures for patients undergoing ABMT for Hodgkin's and non-Hodgkin's lymphoma was consistent with results reported in the medical literature. We observed the cost of a transplant hospitalization to be between $69 002 and $79 884 (not including the cost of cytokine therapy). Smith et al 10 found an average cost of $59 314 for the hospitalization for ABMT in a study of patients with Hodgkin's and non-Hodgkin's lymphoma. However, resource utilization for this study was based on patients treated in Europe, with costs for these resources developed at one clinical center in the United States. Bennett et al have reported ABMT hospitalization costs for patients with Hodgkin's disease as $59 730 and for patients with non-Hodgkin's lymphoma as $80 364 (costs restated in 1995 dollars using the Prospective Payment System Hospital Input Price Index. 25, 26 Blumberg et al 27 reported mean hospital charges of $70 665 and $118 527 for two groups of lymphoma patients undergoing ABMT. Hospital charges are usually greater than hospital costs; however, the relationship between hospital costs and charges differs for each institution. Neither investigator included physician costs in his assessment, nor did he follow patients after hospital discharge.
Data collection for this study occurred in the United States. Thus, we are faced with the question of whether the results can be generalized to clinical settings in other countries. This question is not directly answerable from this study, though it has two components from an economic perspective. First, how general are the total cost data presented in this study? Second, how general are the incremental cost differences across treatment arms? To the extent that bone marrow transplantation is a resource-intensive procedure in all countries, resource utilization data can be generalized to other countries. 10 Since costs differ between countries for these resources as received by patients, the data on total costs may not be as general as the resource data. Economic evaluation is most interested, however, in the incremental costs of a new treatment compared to the existing standard of care. In this assessment, the incremental differences in resource use may again be general between countries. The magnitude of these incremental costs may again be less general between countries.
In terms of cytokine therapy itself, two hypotheses were important in the development of this protocol: IL-3 will decrease resource use during the initial bone marrow transplant procedure; and patients receiving IL-3 will have decreased transfusion requirements following discharge from their hospitalization for ABMT. Interestingly, we found a nonsignificant increase in costs during the initial transplant hospitalization for patients receiving IL-3/GM-CSF therapy. In contrast, we observed a small, but not statistically significant, decrease in post-discharge costs for patients receiving IL-3/GM-CSF therapy. In summary, IL-3 probably has no effect on the costs of care for patients undergoing ABMT for a period of up to 13 months after the procedure. These results are consistent with a model that IL-3 does not add clinical benefit to GM-CSF in terms of platelet recovery or other parameters.
11
This study reports the results of a negative clinical trial. For that reason, the study is important in that it addresses issues related to publication bias in the clinical literature. 28 However, this study also reports on the role of economic evaluation in the development of new technologies. Thus, it provides a model for further studies of supportive therapies for patients undergoing bone marrow transplantation.
Limitations
There are several limitations to this analysis. First, not all patients were observed for the same period, due to the design of the clinical study (which had rolling admission and a fixed stopping date) and to patient drop-out. We used methods for evaluating censored data in our analysis of the trial data to account for this limitation.
Our analysis method assumed random data censoring (ie dropouts were unrelated to treatment arm), which is one of the problems for trials with rolling admissions and fixed stopping dates. However, had censoring not been random (eg due to premature dropout), our analysis might not have appropriately accounted for the censoring of the study data. Furthermore, to the extent that patients who dropped out of the study but were still alive during the 13-month followup period differed after dropout from patients who remained in the protocol, we may have under-or overestimated costs of patients in each treatment arm.
Also, the economic study was a parallel protocol to the clinical protocol and enrolled only 115 of the 206 patients enrolled in the clinical trial, principally due to administrative reasons (initiation of the economic protocol after the clinical protocol) and to a small number of patients' refusals to participate in the study. In our analysis of baseline data, we found two variables with significant differences between patients enrolled in the parallel economic protocol and patients enrolled in the clinical protocol: baseline length of stay and number of cells reinfused. Analyses of these two variables suggests that the date of ABMT may have been responsible for some of the difference in the length of hospitalization for ABMT between patients enrolled and not enrolled in the economic protocol (ie while we were waiting for IRB approval of this parallel protocol, the length of stay decreased overall for study patients). Differences in the number of cells reinfused by treatment group for patients not enrolled in the economic study were consistent with differences we observed in the economic study.
In conclusion, economic analysis of a phase III clinical trial of GM-CSF followed by IL-3 compared with GM-CSF alone showed no significant effect of IL-3 on the costs of care for patients undergoing ABMT for a period of up to 13 months after the procedure. These results are consistent with a model that IL-3 does not add a clinical benefit to GM-CSF in terms of platelet recovery or other clinical parameters. This study provides further documentation of the costs of treatment for patients receiving high-dose chemotherapy and ABMT in the treatment of lymphoma. More importantly, this study demonstrates the feasibility of prospective economic evaluation within phase III trials of new cancer therapies. Data from this type of economic protocol could be used to help physicians, patients, and managed care organizations understand the effect of new treatments from both a clinical and an economic perspective.
